- Home
- PETS vs HOOK Comparison
PETS vs HOOK Comparison
Compare PETS & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- HOOK
- Stock Information
- Founded
- PETS 1996
- HOOK 2011
- Country
- PETS United States
- HOOK United States
- Employees
- PETS N/A
- HOOK N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- HOOK Health Care
- Exchange
- PETS Nasdaq
- HOOK Nasdaq
- Market Cap
- PETS 82.0M
- HOOK 40.8M
- IPO Year
- PETS N/A
- HOOK 2019
- Fundamental
- Price
- PETS $3.98
- HOOK $3.98
- Analyst Decision
- PETS Sell
- HOOK Strong Buy
- Analyst Count
- PETS 2
- HOOK 4
- Target Price
- PETS $3.50
- HOOK $39.25
- AVG Volume (30 Days)
- PETS 174.8K
- HOOK 28.9K
- Earning Date
- PETS 10-28-2024
- HOOK 11-07-2024
- Dividend Yield
- PETS 28.95%
- HOOK N/A
- EPS Growth
- PETS N/A
- HOOK N/A
- EPS
- PETS N/A
- HOOK N/A
- Revenue
- PETS $270,772,000.00
- HOOK $52,163,000.00
- Revenue This Year
- PETS N/A
- HOOK $155.36
- Revenue Next Year
- PETS $3.27
- HOOK N/A
- P/E Ratio
- PETS N/A
- HOOK N/A
- Revenue Growth
- PETS 2.26
- HOOK 227.80
- 52 Week Low
- PETS $2.90
- HOOK $3.42
- 52 Week High
- PETS $10.53
- HOOK $11.30
- Technical
- Relative Strength Index (RSI)
- PETS 54.93
- HOOK 42.37
- Support Level
- PETS $3.89
- HOOK $3.92
- Resistance Level
- PETS $4.22
- HOOK $4.32
- Average True Range (ATR)
- PETS 0.20
- HOOK 0.25
- MACD
- PETS -0.02
- HOOK 0.05
- Stochastic Oscillator
- PETS 47.37
- HOOK 62.43
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.